Drug reference

Daratumumab

Monoclonal Antibody · Multiple myeloma agent

Monoclonal AntibodyMultiple myeloma agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter
CladribineSevereDatabaseDDInter

Mechanism

Daratumumab is an IgG1 human monoclonal antibody that binds to CD38, a cell-surface glycoprotein highly expressed on multiple myeloma cells. This binding results in tumour cell death through immune-mediated actions and apoptosis.

Indications

Multiple myeloma (as monotherapy after failure of a proteasome inhibitor and an immunomodulatory agent)Multiple myeloma (in combination with lenalidomide and dexamethasone in patients who have received at least one prior therapy)Multiple myeloma (in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy)Newly diagnosed multiple myeloma (in combination with bortezomib, melphalan and prednisone)multiple myeloma (MM) in combination with other agents such as lenalidomide or bortezomib and dexamethasoneNewly diagnosed multiple myelomaMaintenance therapy for multiple myelomaRelapsed multiple myeloma

Dosing

Adult: For multiple myeloma (as monotherapy after failure of a proteasome inhibitor and an immunomodulatory agent, or in combination with lenalidomide and dexamethasone in patients who have received at least one prior therapy): 16 mg/kg once weekly for weeks 1 to 8 (for week 1, dose can alternatively be divided over 2 consecutive days), then 16 mg/kg every 2 weeks for weeks 9 to 24, then 16 mg/kg every 4…